Patrick G. Enright
Director at Veradermics; Director at Vera Therapeutics; Director at Zenas BioPharma. Based in Menlo Park, California.
- Rank
- 13563rd of 14,644
- Companies held
- 3
- Largest holding
- JAZZ, 91.7% of total
- Latest SEC filing
- Nov 11, 2026
- Listed but not counted
- $734M
What the $5.5M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals JAZZ Ordinary Shares | Directly | 21,278 | $236.45 | $5.0M | 91.7% | Form 4, Aug 31, 2026 |
| Zenas BioPharma ZBIO Common Stock | Directly | 11,990 | $25.04 | $300K | 5.5% | Form 4, Oct 9, 2025 |
| Vera Therapeutics VERA Class A Common Stock | Directly | 5,882 | $26.75 | $157K | 2.9% | Form 4, Dec 11, 2025 |
Share counts are the amounts Patrick G. Enright reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Patrick G. Enright's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Veradermics MANE Common Stock | Through Longitude Venture Partners V, L.P. Held by a company or fund the insider manages | 2,350,399 | $124.38 | $292M | — | Form 4, Nov 11, 2026 |
| Veradermics MANE Common Stock | Through Longitude 103.8 East, L.P. Held by a company or fund the insider manages | 1,803,474 | $124.38 | $224M | — | Form 4, Nov 11, 2026 |
| Vera Therapeutics VERA Class A Common Stock | Indirectly (see filing footnote) Held by a company or fund the insider manages | 3,596,593 | $26.75 | $96.2M | — | Form 4, Dec 11, 2025 |
| Vera Therapeutics VERA Class A Common Stock | Through Longitude Prime Fund, L.P. Held by a company or fund the insider manages | 1,797,619 | $26.75 | $48.1M | — | Form 4, Dec 11, 2025 |
| Zenas BioPharma ZBIO Common Stock | Through LVPIV. Longitude Capital Partners IV, LLC Held by a company or fund the insider manages | 1,832,669 | $25.04 | $45.9M | — | Form 4, Oct 9, 2025 |
| Zenas BioPharma ZBIO Common Stock | Through Longitude Prime Fund, L.P. Held by a company or fund the insider manages | 774,530 | $25.04 | $19.4M | — | Form 4, Oct 9, 2025 |
| BioAge Labs BIOA Common Stock | Longitude Venture Partners IV, L.P. Held by a company or fund the insider manages | 1,710,589 | $4.71 | $8.1M | — | Form 4, Sep 27, 2024 |
Open-market trades, last 12 months
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 13560 | Lisa A. Grow President & CEO, IDACORP. Camden, NJ | $5.5M |
| 13561 | Kurt M. Eckert Director, Miami International Holdings. Princeton, NJ | $5.5M |
| 13562 | Adam M. Vela SVP & GENERAL COUNSEL, Devon Energy. Houston, TX | $5.5M |
| 13563 | Patrick G. Enright Director, Veradermics. Menlo Park, CA | $5.5M |
| 13564 | Simon Jonathan Allen Director, McGraw Hill. Columbus, OH | $5.5M |
| 13565 | W. Howard Morris Director, Owens Corning. Hartford, CT | $5.5M |
| 13566 | Rodney C. Adkins Director, Avnet. Phoenix, AZ | $5.5M |
Other Veradermics insiders
All MANE insiders- John W. Childs$261MDirector. #538 overall
- Vlad Coric$88.3MDirector. #1153 overall
- Timothy August Durso$24.2MChief Technical Officer. #4480 overall
- Reid Alexander Waldman$21.2MChief Executive Officer. #4956 overall
Questions
How much stock does Patrick G. Enright own?
Patrick G. Enright holds $5,488,756 in listed stock based on SEC filings and current prices, mostly Jazz Pharmaceuticals (JAZZ). That ranks 13563rd on the Stock Rich List.
Is this Patrick G. Enright's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Patrick G. Enright last buy or sell stock?
The most recent open-market trade on file is a sale of 250,000 MANE shares on Nov 11, 2026 at $150.38.